These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

129 related articles for article (PubMed ID: 21658307)

  • 1. Anti-TNF-alpha antibody (infliximab) therapy supports the recovery of eNOS and VEGFR2 protein expression in endothelial cells.
    Altorjay I; Veréb Z; Serfozo Z; Bacskai I; Bátori R; Erdodi F; Udvardy M; Sipka S; Lányi Á; Rajnavölgyi É; Palatka K
    Int J Immunopathol Pharmacol; 2011; 24(2):323-35. PubMed ID: 21658307
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of IBD sera on expression of inducible and endothelial nitric oxide synthase in human umbilical vein endothelial cells.
    Palatka K; Serfozo Z; Veréb Z; Bátori R; Lontay B; Hargitay Z; Nemes Z; Udvardy M; Erdodi F; Altorjay I
    World J Gastroenterol; 2006 Mar; 12(11):1730-8. PubMed ID: 16586542
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Tumor necrosis factor-alpha antagonism improves endothelial dysfunction in patients with Crohn's disease.
    Schinzari F; Armuzzi A; De Pascalis B; Mores N; Tesauro M; Melina D; Cardillo C
    Clin Pharmacol Ther; 2008 Jan; 83(1):70-6. PubMed ID: 17507924
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The effects of infliximab or adalimumab on vascular endothelial growth factor and angiopoietin 1 angiogenic factor levels in inflammatory bowel disease: serial observations in 37 patients.
    Algaba A; Linares PM; Encarnación Fernández-Contreras M; Figuerola A; Calvet X; Guerra I; de Pousa I; Chaparro M; Gisbert JP; Bermejo F
    Inflamm Bowel Dis; 2014 Apr; 20(4):695-702. PubMed ID: 24562175
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mucosal expression of basic fibroblastic growth factor, syndecan 1 and tumour necrosis factor-α in Crohn's disease in deep remission under treatment with anti-TNFα antibodies.
    Tursi A; Elisei W; Principi M; Inchingolo CD; Nenna R; Picchio M; Giorgio F; Ierardi E; Brandimarte G
    J Gastrointestin Liver Dis; 2014 Sep; 23(3):261-5. PubMed ID: 25267953
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Infliximab downregulates basic fibroblast growth factor and vascular endothelial growth factor in Crohn's disease patients.
    Di Sabatino A; Ciccocioppo R; Benazzato L; Sturniolo GC; Corazza GR
    Aliment Pharmacol Ther; 2004 May; 19(9):1019-24. PubMed ID: 15113369
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Basic fibroblast growth factor as a response parameter to infliximab in fistulizing Crohn's disease.
    Gao Q; Hogezand RA; Lamers CB; Verspaget HW
    Aliment Pharmacol Ther; 2004 Sep; 20(5):585-92. PubMed ID: 15339330
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Isoprenoid depletion by statins antagonizes cytokine-induced down-regulation of endothelial nitric oxide expression and increases NO synthase activity in human umbilical vein endothelial cells.
    Jantzen F; Könemann S; Wolff B; Barth S; Staudt A; Kroemer HK; Dahm JB; Felix SB; Landsberger M
    J Physiol Pharmacol; 2007 Sep; 58(3):503-14. PubMed ID: 17928646
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Anti-TNF-alpha loss of response is associated with a decreased percentage of FoxP3+ T cells and a variant NOD2 genotype in patients with Crohn's disease.
    Juanola O; Moratalla A; Gutiérrez A; Sempere L; Zapater P; Giménez P; Almenta I; Peiró G; González-Navajas JM; Such JF; Francés R
    J Gastroenterol; 2015 Jul; 50(7):758-68. PubMed ID: 25500977
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Angiotensin II type 1 receptor blockers prevent tumor necrosis factor-alpha-mediated endothelial nitric oxide synthase reduction and superoxide production in human umbilical vein endothelial cells.
    Kataoka H; Murakami R; Numaguchi Y; Okumura K; Murohara T
    Eur J Pharmacol; 2010 Jun; 636(1-3):36-41. PubMed ID: 20353766
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Management of inflammatory bowel disease with infliximab and other anti-tumor necrosis factor alpha therapies.
    Magro F; Portela F
    BioDrugs; 2010 Dec; 24 Suppl 1():3-14. PubMed ID: 21175228
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Infliximab therapy downregulation of basic fibroblast growth factor/syndecan 1 link: a possible molecular pathway of mucosal healing in ulcerative colitis.
    Ierardi E; Giorgio F; Zotti M; Rosania R; Principi M; Marangi S; Della Valle N; De Francesco V; Di Leo A; Ingrosso M; Panella C
    J Clin Pathol; 2011 Nov; 64(11):968-72. PubMed ID: 21945924
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Protein kinase C alpha promotes angiogenic activity of human endothelial cells via induction of vascular endothelial growth factor.
    Xu H; Czerwinski P; Hortmann M; Sohn HY; Förstermann U; Li H
    Cardiovasc Res; 2008 May; 78(2):349-55. PubMed ID: 18056764
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Vascular endothelial growth factor receptor-2 and low affinity VEGF binding sites on human glomerular endothelial cells: Biological effects and advanced glycosilation end products modulation.
    Pala L; Cresci B; Manuelli C; Maggi E; Yamaguchi YF; Cappugi P; Rotella CM; Giannini S
    Microvasc Res; 2005 Nov; 70(3):179-88. PubMed ID: 16271941
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Resolution of endothelial activation and down-regulation of Tie2 receptor in psoriatic skin after infliximab therapy.
    Markham T; Mullan R; Golden-Mason L; Rogers S; Bresnihan B; Fitzgerald O; Fearon U; Veale DJ
    J Am Acad Dermatol; 2006 Jun; 54(6):1003-12. PubMed ID: 16713454
    [TBL] [Abstract][Full Text] [Related]  

  • 16. High serum TNF-alpha level in Type 2 diabetic patients with microangiopathy is associated with eNOS down-regulation and apoptosis in endothelial cells.
    Makino N; Maeda T; Sugano M; Satoh S; Watanabe R; Abe N
    J Diabetes Complications; 2005; 19(6):347-55. PubMed ID: 16260352
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Berberine protects endothelial progenitor cell from damage of TNF-α via the PI3K/AKT/eNOS signaling pathway.
    Xiao M; Men LN; Xu MG; Wang GB; Lv HT; Liu C
    Eur J Pharmacol; 2014 Nov; 743():11-6. PubMed ID: 25257463
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Anti-TNF-α antibodies improve intestinal barrier function in Crohn's disease.
    Noth R; Stüber E; Häsler R; Nikolaus S; Kühbacher T; Hampe J; Bewig B; Schreiber S; Arlt A
    J Crohns Colitis; 2012 May; 6(4):464-9. PubMed ID: 22398062
    [TBL] [Abstract][Full Text] [Related]  

  • 19. High serum tumor necrosis factor-alpha levels are associated with lack of response to infliximab in fistulizing Crohn's disease.
    Martínez-Borra J; López-Larrea C; González S; Fuentes D; Dieguez A; Deschamps EM; Pérez-Pariente JM; López-Vázquez A; de Francisco R; Rodrigo L
    Am J Gastroenterol; 2002 Sep; 97(9):2350-6. PubMed ID: 12358255
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Distinctive histopathologic phenotype in resection specimens from patients with Crohn's disease receiving anti-TNF-α therapy.
    Schaeffer DF; Walsh JC; Kirsch R; Waterman M; Silverberg MS; Riddell RH
    Hum Pathol; 2014 Sep; 45(9):1928-35. PubMed ID: 25022570
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.